EP1017682A4 - Neue angiogenese-inhibitoren - Google Patents
Neue angiogenese-inhibitorenInfo
- Publication number
- EP1017682A4 EP1017682A4 EP98948427A EP98948427A EP1017682A4 EP 1017682 A4 EP1017682 A4 EP 1017682A4 EP 98948427 A EP98948427 A EP 98948427A EP 98948427 A EP98948427 A EP 98948427A EP 1017682 A4 EP1017682 A4 EP 1017682A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiogenesis inhibitors
- novel angiogenesis
- novel
- inhibitors
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6015197P | 1997-09-26 | 1997-09-26 | |
US60151P | 1997-09-26 | ||
GBGB9810544.8A GB9810544D0 (en) | 1998-05-15 | 1998-05-15 | Novel angiogenesis inhibitors |
GB9810544 | 1998-05-15 | ||
PCT/US1998/019789 WO1999016755A1 (en) | 1997-09-26 | 1998-09-22 | Novel angiogenesis inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1017682A1 EP1017682A1 (de) | 2000-07-12 |
EP1017682A4 true EP1017682A4 (de) | 2000-11-08 |
Family
ID=26313694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98948427A Withdrawn EP1017682A4 (de) | 1997-09-26 | 1998-09-22 | Neue angiogenese-inhibitoren |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1017682A4 (de) |
JP (1) | JP2001518470A (de) |
AU (1) | AU744939B2 (de) |
CA (1) | CA2303830A1 (de) |
WO (1) | WO1999016755A1 (de) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1178791A2 (de) * | 1999-05-07 | 2002-02-13 | Johns Hopkins University School of Medicine | Verwendung eines hemmenders der proteinkinaseweg zur behandlung von krankheiten der augen |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
WO2001057020A1 (en) * | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
ATE430742T1 (de) | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
AR032028A1 (es) | 2001-01-05 | 2003-10-22 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
RU2259825C9 (ru) | 2001-06-18 | 2006-04-10 | БиоДием Лимитед | Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности |
WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
WO2003045929A1 (fr) * | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Derive bicyclique, procede de production de ce derive et utilisation correspondante |
MXPA04008403A (es) | 2002-03-01 | 2004-11-26 | Pfizer | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso. |
ES2373875T3 (es) * | 2002-03-05 | 2012-02-09 | Transtech Pharma, Inc. | Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage. |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
CA2501932C (en) | 2002-11-13 | 2014-03-11 | Chiron Corporation | Use of benzimidazole quinolinones for treating cancer |
JP3814285B2 (ja) | 2002-12-19 | 2006-08-23 | ファイザー・インク | 眼疾患の治療に有用なプロテインキナーゼ阻害剤としての2−(1h−インダゾール−6−イルアミノ)−ベンズアミド化合物 |
GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
DE602004017479D1 (de) | 2003-08-29 | 2008-12-11 | Pfizer | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
BRPI0418102A (pt) | 2003-12-23 | 2007-04-27 | Pfizer | derivados de quinolina |
US7560568B2 (en) | 2004-01-28 | 2009-07-14 | Smithkline Beecham Corporation | Thiazole compounds |
US7875624B2 (en) | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
EP1756054B1 (de) | 2004-06-01 | 2010-03-31 | F.Hoffmann-La Roche Ag | 3-amino-1-arylpropyl-indole als monoamin-wiederaufnahmehemmer |
KR20070027584A (ko) | 2004-06-17 | 2007-03-09 | 와이어쓰 | 고나도트로핀 방출 호르몬 수용체 길항제 |
CA2570693A1 (en) | 2004-06-17 | 2006-01-26 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
ATE463486T1 (de) | 2004-08-26 | 2010-04-15 | Pfizer | Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer |
US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
NZ562453A (en) | 2005-03-31 | 2010-04-30 | Agensys Inc | Antibodies and related molecules that bind to 161P2F10B proteins |
BRPI0608096A2 (pt) | 2005-04-26 | 2009-11-10 | Pfizer | anticorpos p-caderina |
US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
EP2266974A1 (de) | 2005-05-23 | 2010-12-29 | Novartis AG | Kristalline und andere Formen von 4-Amino-5-Fluor-3-[6-(Methylpiperazin-1-yl)-1H-Benzimidazol-2-yl]-1H-Chinolin-2-Onmilchsäuresalz |
US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
UA94060C2 (ru) | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Моноклональное антитело, которое специфически связывает alk-1 |
WO2007035744A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
RU2008120141A (ru) | 2005-11-30 | 2010-01-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | 3-амино-2-арилпропилазаиндолы и их применения |
CN101316819B (zh) | 2005-11-30 | 2011-05-18 | 弗·哈夫曼-拉罗切有限公司 | 合成3-氨基-1-芳基丙基吲哚类的方法 |
CN101316818B (zh) | 2005-11-30 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 3-氨基-1-芳基丙基吲哚类和氮杂取代的吲哚类 |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
PT2185574E (pt) | 2007-09-07 | 2013-08-26 | Agensys Inc | Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12 |
TWI445532B (zh) | 2007-09-14 | 2014-07-21 | Janssen Pharmaceuticals Inc | 1’,3’-二取代-4-苯基-3,4,5,6-四氫-2h,1’h-〔1,4’〕聯吡啶基-2’-酮化物 |
CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
US8507473B2 (en) | 2008-09-11 | 2013-08-13 | Arena Pharmaceuticals, Inc. | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders |
CA2737597C (en) | 2008-10-16 | 2017-03-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
SG172857A1 (en) | 2009-02-09 | 2011-08-29 | Supergen Inc | Pyrrolopyrimidinyl axl kinase inhibitors |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US20100222381A1 (en) | 2009-02-27 | 2010-09-02 | Hariprasad Vankayalapati | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
SG176018A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MX2011011964A (es) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. |
SG10201510152RA (en) | 2009-07-13 | 2016-01-28 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
WO2011014726A1 (en) | 2009-07-31 | 2011-02-03 | Osi Pharmaceuticals, Inc. | Mtor inhibitor and angiogenesis inhibitor combination therapy |
WO2011027249A2 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
AU2010292060A1 (en) | 2009-09-11 | 2012-04-12 | Genentech, Inc. | Method to identify a patient with an increased likelihood of responding to an anti-cancer agent |
CN102612566B (zh) | 2009-09-17 | 2016-02-17 | 霍夫曼-拉罗奇有限公司 | 用于癌症患者中诊断学用途的方法和组合物 |
JP5805646B2 (ja) | 2009-09-30 | 2015-11-04 | ブイティーブイ・セラピューティクス・エルエルシー | アルツハイマー病の治療のための置換イミダゾール誘導体 |
WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
WO2011098971A1 (en) | 2010-02-12 | 2011-08-18 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
US20110217309A1 (en) | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
JP2013527748A (ja) | 2010-03-03 | 2013-07-04 | オーエスアイ・ファーマシューティカルズ,エルエルシー | インスリン様増殖因子1受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
ES2611479T3 (es) | 2010-06-16 | 2017-05-09 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Anticuerpos contra endoplasmina y su uso |
SG187018A1 (en) | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
JP2013538338A (ja) | 2010-07-19 | 2013-10-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌治療への応答可能性の増大した患者を同定する方法 |
WO2012012750A1 (en) | 2010-07-23 | 2012-01-26 | Trustees Of Boston University | ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
EP2630134B9 (de) | 2010-10-20 | 2018-04-18 | Pfizer Inc | Pyridine-2- derivate als modulatoren des smoothened rezeptors |
ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
EP2699598B1 (de) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
WO2013042006A1 (en) | 2011-09-22 | 2013-03-28 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
EP3275902A1 (de) | 2011-10-04 | 2018-01-31 | IGEM Therapeutics Limited | Ige anti-hmw-maa antikörper |
BR112014011115A2 (pt) | 2011-11-08 | 2017-06-13 | Pfizer | métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf |
KR20130076046A (ko) * | 2011-12-28 | 2013-07-08 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. | 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法 |
US11642340B2 (en) | 2012-09-26 | 2023-05-09 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
US10835525B2 (en) | 2012-09-26 | 2020-11-17 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型c-kit的方法 |
US9394257B2 (en) | 2012-10-16 | 2016-07-19 | Tolero Pharmaceuticals, Inc. | PKM2 modulators and methods for their use |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
GB201223265D0 (en) * | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
US10202356B2 (en) | 2013-03-14 | 2019-02-12 | Tolero Pharmaceuticals, Inc. | JAK2 and ALK2 inhibitors and methods for their use |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
UA127921C2 (uk) | 2014-01-21 | 2024-02-14 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
DK3096790T3 (da) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
CN111808957A (zh) | 2014-04-04 | 2020-10-23 | 中美冠科生物技术(太仓)有限公司 | 用于确定对mek/erk抑制剂的应答性的方法 |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
PT3137460T (pt) | 2014-04-30 | 2019-12-30 | Pfizer | Derivados de di-heterociclo ligado a cicloalquilo |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
ES2848857T3 (es) | 2014-07-31 | 2021-08-12 | Us Gov Health & Human Services | Anticuerpos monoclonales humanos contra EphA4 y su uso |
ES2746839T3 (es) | 2014-12-18 | 2020-03-09 | Pfizer | Derivados de pirimidina y triazina y su uso como inhibidores de AXL |
MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
US10011629B2 (en) | 2015-05-01 | 2018-07-03 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
JP2018526452A (ja) * | 2015-09-03 | 2018-09-13 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Dyrk1aの小分子抑制剤およびその使用 |
JP6877429B2 (ja) | 2015-12-03 | 2021-05-26 | アジオス ファーマシューティカルズ, インコーポレイテッド | Mtapヌル癌を処置するためのmat2a阻害剤 |
WO2018085292A1 (en) | 2016-11-02 | 2018-05-11 | Arog Pharmaceuticals, Inc. | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
US10132797B2 (en) | 2016-12-19 | 2018-11-20 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
CN110840893A (zh) | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
EP3924351A4 (de) | 2019-02-12 | 2022-12-21 | Sumitomo Pharma Oncology, Inc. | Formulierungen mit heterocyclischen proteinkinaseinhibitoren |
WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
AU2020245437A1 (en) | 2019-03-22 | 2021-09-30 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
US11465998B2 (en) | 2019-04-25 | 2022-10-11 | Regents Of The University Of Minnesota | Therapeutic compounds and methods of use thereof |
US11471451B2 (en) | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
JP2023063189A (ja) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性/不応性のflt3突然変異増殖性障害を治療するためのクレノラニブ |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0563001A1 (de) * | 1992-03-26 | 1993-09-29 | Neurosearch A/S | Imidazol-Derivate, ihre Herstellung und Verwendung |
EP0616807A1 (de) * | 1993-03-24 | 1994-09-28 | Neurosearch A/S | Zur Behandlung von Erkrankungen des Zentralnervensystems verwendbare Benzimidazole |
EP0635507A1 (de) * | 1993-07-19 | 1995-01-25 | Zeneca Limited | Tricyclische Derivate und ihre Anwendung als Krebsmittel |
WO1998017651A1 (en) * | 1996-10-21 | 1998-04-30 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as baga-a receptor modulators |
-
1998
- 1998-09-22 EP EP98948427A patent/EP1017682A4/de not_active Withdrawn
- 1998-09-22 WO PCT/US1998/019789 patent/WO1999016755A1/en not_active Application Discontinuation
- 1998-09-22 CA CA002303830A patent/CA2303830A1/en not_active Abandoned
- 1998-09-22 JP JP2000513841A patent/JP2001518470A/ja not_active Withdrawn
- 1998-09-22 AU AU95003/98A patent/AU744939B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0563001A1 (de) * | 1992-03-26 | 1993-09-29 | Neurosearch A/S | Imidazol-Derivate, ihre Herstellung und Verwendung |
EP0616807A1 (de) * | 1993-03-24 | 1994-09-28 | Neurosearch A/S | Zur Behandlung von Erkrankungen des Zentralnervensystems verwendbare Benzimidazole |
EP0635507A1 (de) * | 1993-07-19 | 1995-01-25 | Zeneca Limited | Tricyclische Derivate und ihre Anwendung als Krebsmittel |
WO1998017651A1 (en) * | 1996-10-21 | 1998-04-30 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as baga-a receptor modulators |
Non-Patent Citations (1)
Title |
---|
See also references of WO9916755A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2001518470A (ja) | 2001-10-16 |
AU9500398A (en) | 1999-04-23 |
CA2303830A1 (en) | 1999-04-08 |
EP1017682A1 (de) | 2000-07-12 |
AU744939B2 (en) | 2002-03-07 |
WO1999016755A1 (en) | 1999-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0984692A4 (de) | Angiogenese-inhibitoren | |
EP1017682A4 (de) | Neue angiogenese-inhibitoren | |
EP1109555A4 (de) | Neue angiogeneseinhibitoren | |
EP1097147A4 (de) | Neue angiogenese-inhibitoren | |
ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
DE69803272D1 (en) | Hemmstoffe der stickstoffmonoxid-synthase | |
GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
PL335999A1 (en) | Substituted 3-cyanoquinolines | |
AP2000001795A0 (en) | Substituted 4-aminothiazol-2-yol | |
PL331338A1 (en) | Thiosulphonamidic metaloprotease inhibitors | |
PL316669A1 (en) | Angiogenesis inhibitors | |
MX202707B (en) | Scale inhibitors | |
HUP0202076A3 (en) | Triazine angiogenesis inhibitors | |
HK1026889A1 (en) | Novel aryloxy-alkyl-dialkylamines | |
PL331803A1 (en) | Bidonoric metaloprotease inhibitors | |
SI1036083T1 (en) | Novel 9a-azalides | |
PL345574A1 (en) | Angiogenesis inhibitors | |
PL334546A1 (en) | Substituted 4-benzoylpyrazoles | |
ZA985761B (en) | Substituted aryluracils | |
IL133261A0 (en) | Substituted naphthropyrans | |
GB9800681D0 (en) | Novel angiogenesis inhibitors | |
GB9810544D0 (en) | Novel angiogenesis inhibitors | |
GB9822700D0 (en) | Novel angiogenesis inhibitors | |
AUPO820197A0 (en) | Inorganic angiogenesis inhibitors | |
PL318601A1 (en) | Novel 5-arylidene-4-oxo-2-imidazpglycines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000426 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20000426;LT PAYMENT 20000426;LV PAYMENT 20000426;MK PAYMENT 20000426;RO PAYMENT 20000426;SI PAYMENT 20000426 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000922 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030227 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040813 |